Nuvectis Pharma, Inc. (NVCT) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Fort Lee, NJ, United States. The current CEO is Ron Bentsur.
NVCT has IPO date of 2022-02-04, 13 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $231.27M.
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
